3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
108
Stomach Neoplasms
68
Pancreatic Neoplasms
33
Neoplasms
24
Lymphoma, Large B-Cell, Diffuse
22
Carcinoma, Non-Small-Cell Lung
21
Neoplasm Metastasis
18
Rectal Neoplasms
17
Colonic Neoplasms
17
Esophageal Neoplasms
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Adenocarcinoma
13
Carcinoma, Hepatocellular
12
Ovarian Neoplasms
10
Biliary Tract Neoplasms
9
Adenocarcinoma Of Esophagus
9
Esophageal Squamous Cell Carcinoma
8
Cholangiocarcinoma
8
Gastrointestinal Neoplasms
7
Lymphoma, Non-Hodgkin
6
Endometrial Neoplasms
6
Gallbladder Neoplasms
5
Advanced Solid Tumors
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Recurrence
4
Carcinoma, Pancreatic Ductal
4
Breast Neoplasms
4
Advanced Solid Tumor
4
Solid Tumors
3
Interventions
lutetium Lu 177 dotatate
3
Octreotide
3
pasireotide
2
lanreotide
2
amino-acid, glucose, and electrolyte solution
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
famitinib
1
copper dotatate CU-64
1
arginyllysine
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
PM 01183
1
Oxaliplatin
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Irinotecan
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gastro-enteropancreatic neuroendocrine tumor
×
Oxaliplatin
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled